Skip to main content
Clinical Trials/NCT01828593
NCT01828593
Completed
Not Applicable

Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.

Entera Health, Inc4 sites in 1 country103 target enrollmentApril 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV-associated Enteropathy
Sponsor
Entera Health, Inc
Enrollment
103
Locations
4
Primary Endpoint
Frequency of Daily Unformed Bowel Movements
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of the study is to evaluate the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g twice a day (BID) and SBI 5.0 g versus placebo on supporting nutrient absorption in HIV+ subjects with HIV-associated enteropathy.

Detailed Description

This study is evaluating the effectiveness of the oral nutritional therapy serum-derived bovine immunoglobulin protein isolate (SBI) 2.5g BID and SBI 5.0g compared to placebo for 6 months on gastrointestinal symptoms, nutritional status and quality of life in HIV+ subjects with HIV-associated enteropathy. In addition, the effects of SBI on pro-inflammatory intestinal microbial populations, bacterial translocation, intestinal barrier function, and systemic immune activation will be investigated.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
September 2014
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Entera Health, Inc
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • History of HIV-1 infection
  • Plasma HIV viral load ≤40 copies/mL
  • Maintained virologic suppression for 1 year
  • Stable Antiretroviral Therapy (ART) regimen
  • History of HIV-associated diarrhea defined as abnormal passage of 3 or more unformed stools per day or a liquid stool volume greater than 200 g per day for at least 4 weeks duration

Exclusion Criteria

  • Positive stool test for pathogenic bacteria, C. difficile or ova and parasites
  • Conditions that require chronic therapy that is known to alter gut microbiota
  • Antibiotics within 2 weeks of screening (exception: prophylaxis antibiotics)

Outcomes

Primary Outcomes

Frequency of Daily Unformed Bowel Movements

Time Frame: Baseline and 4 weeks

Change in number of abnormal or unformed stools by week 4

Study Sites (4)

Loading locations...

Similar Trials